Data / Drug companies / AbbVie Inc.
AbbVie Inc.: 124 products in the FDA NDC directory, labeler code 0074
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
AbbVie Inc. (labeler code 0074) lists 124 products in the FDA National Drug Code Directory, covering 23 finished drugs by generic name. By type: 91 prescription drugs, 28 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on October 23, 2026.
The request: Watch AbbVie Inc. (FDA labeler code 0074): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0074
- Products in commercial distribution
- 124
- Packages
- 190
- Finished drugs by generic name
- 23
- Prescription products
- 91
- Over the counter products
- 0
- Flagged as original packager
- 75 of 75 products that carry the flag
- Started marketing in the last 12 months
- 17
- Products with a marketing end date set
- 2
- Earliest marketing start
- March 10, 1983
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 65 | 52.4% |
| Drugs for further processing | 27 | 21.8% |
| Biologics (BLA) | 24 | 19.4% |
| Bulk ingredients | 5 | 4% |
| Generic drugs (ANDA) | 2 | 1.6% |
| Export only | 1 | 0.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 91 | 73.4% |
| Drugs for further processing | 28 | 22.6% |
| Bulk ingredients | 5 | 4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Levothyroxine sodium | 12 | 44 |
| Leuprolide acetate | 12 | 16 |
| Risankizumab-rzaa | 11 | 1 |
| Adalimumab | 9 | 4 |
| Divalproex sodium | 6 | 48 |
| Tavapadon | 5 | 1 |
| Paricalcitol | 4 | 13 |
| Venetoclax | 4 | 1 |
| Upadacitinib | 4 | 1 |
| Atogepant | 3 | 1 |
| Lopinavir and ritonavir | 3 | 4 |
| Cyclosporine | 2 | 24 |
| Elagolix | 2 | 1 |
| Glecaprevir and pibrentasvir | 2 | 1 |
| Ritonavir | 2 | 8 |
| Telisotuzumab vedotin | 2 | 1 |
| Sevoflurane | 2 | 9 |
| Foscarbidopa/foslevodopa | 1 | 1 |
| Pivekimab sunirine-pvzy | 1 | 1 |
| Beractant | 1 | 1 |
| Carbidopa and levodopa | 1 | 41 |
| Elagolix and estradiol and norethisterone | 1 | 1 |
| Aztreonam and avibactam | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Kit | 29 | 23.4% |
| Tablet | 27 | 21.8% |
| Tablet, film coated | 13 | 10.5% |
| Injection, solution | 10 | 8.1% |
| Liquid | 7 | 5.6% |
| Capsule | 6 | 4.8% |
| Injection | 6 | 4.8% |
| Tablet, extended release | 6 | 4.8% |
| Tablet, delayed release | 6 | 4.8% |
| Powder | 3 | 2.4% |
| Injection, powder, lyophilized, for solution | 3 | 2.4% |
| Solution | 2 | 1.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Skyrizi | 0074-1084 | Kit | Biologics (BLA) | October 23, 2026 |
| Ubrogepant | 0074-6498 | Tablet | Drugs for further processing | September 29, 2026 |
| Juvmo | 0074-6315 | Tablet | New drug applications (NDA) | September 25, 2026 |
| Juvmo | 0074-6210 | Tablet | New drug applications (NDA) | September 25, 2026 |
| Juvmo | 0074-6105 | Tablet | New drug applications (NDA) | September 25, 2026 |
| Juvmo | 0074-6090 | Kit | New drug applications (NDA) | September 25, 2026 |
| Juvmo | 0074-5925 | Tablet | New drug applications (NDA) | September 25, 2026 |
| Divalproex sodium | 0074-7347 | Tablet, delayed release | Drugs for further processing | September 22, 2026 |
| Divalproex sodium | 0074-7346 | Tablet, delayed release | Drugs for further processing | September 22, 2026 |
| Divalproex sodium | 0074-7345 | Tablet, delayed release | Drugs for further processing | September 22, 2026 |
| Ubrogepant | 0074-6501 | Tablet | Drugs for further processing | September 9, 2026 |
| Ibrutinib | 0074-2585 | Tablet | Drugs for further processing | September 1, 2026 |
| Venetoclax | 0074-1137 | Tablet, film coated | Drugs for further processing | July 13, 2026 |
| Venetoclax | 0074-1087 | Tablet, film coated | Drugs for further processing | July 13, 2026 |
| Skyrizi | 0074-4059 | Injection, solution | Biologics (BLA) | June 12, 2026 |
| Decnupaz | 0074-0282 | Injection, powder, lyophilized, for solution | Biologics (BLA) | May 27, 2026 |
| Venetoclax | 0074-0598 | Powder | Drugs for further processing | April 1, 2026 |
| Skyrizi | 0074-8350 | Injection | Biologics (BLA) | September 3, 2025 |
| Skyrizi | 0074-8300 | Injection | Biologics (BLA) | September 3, 2025 |
| Emrelis | 0074-1055 | Injection, powder, lyophilized, for solution | Biologics (BLA) | May 14, 2025 |
| Emrelis | 0074-1044 | Injection, powder, lyophilized, for solution | Biologics (BLA) | May 14, 2025 |
| Risankizumab | 0074-5025 | Injection, solution | Drugs for further processing | April 4, 2025 |
| Emblaveo | 0074-3878 | Powder, for solution | New drug applications (NDA) | February 7, 2025 |
| Risankizumab | 0074-9011 | Liquid | Drugs for further processing | February 4, 2025 |
| Risankizumab | 0074-1078 | Liquid | Bulk ingredients | December 9, 2024 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.